Group 1 - The core message emphasizes the importance of early screening for liver diseases, highlighted by the participation of Camille, an executive from the French subsidiary of Furuya Co., in the London Marathon [1] - Furuya Co.'s FibroScan technology is recognized as the "gold standard" for liver disease diagnosis, facilitating non-invasive liver fibrosis detection and contributing to the Healthy China strategy [1] - The World Health Organization (WHO) reports that approximately 800,000 people die from liver cancer annually, with China accounting for nearly half of these cases, underscoring the urgency of addressing liver health [1] Group 2 - FibroScan technology marks a shift from subjective doctor-dependent assessments to AI-driven precision in liver disease detection, identifying liver fat changes as low as 5% [2] - The introduction of FibroScan in leading domestic health institutions like Aikang Guobin enhances efficiency by over 80%, providing quick assessments of liver health in just 3-5 minutes [2] - Furuya Co. is actively involved in the EU LIVERAIM project, the largest liver disease clinical trial to date, aiming to develop a personalized early diagnosis screening platform using AI, with over 100,000 participants [2]

Core Insights - The company reported steady growth in revenue and profit for 2024, with operating income of 1.349 billion yuan (yoy +16.93%) and net profit attributable to shareholders of 113 million yuan (yoy +11.54%) [1][2] - In Q1 2025, the company experienced a slight increase in revenue but a significant decline in net profit, with operating income of 330 million yuan (yoy +2.35%) and net profit of 28.64 million yuan (yoy -32.97%) [1][2] Financial Performance - For 2024, the company's gross margin was 74.13%, a decrease of 0.62 percentage points; the sales expense ratio was 25.47%, down 2.39 percentage points; the management expense ratio increased to 17.84%, up 4.27 percentage points; the R&D expense ratio was 7.37%, up 0.23 percentage points; and the net profit margin was 14.52%, down 0.83 percentage points [2] - In Q1 2025, the gross margin improved to 76.76%, an increase of 0.16 percentage points; the sales expense ratio rose to 25.87%, up 1.66 percentage points; the management expense ratio increased to 22.54%, up 4.27 percentage points; the R&D expense ratio decreased to 6.71%, down 1.17 percentage points; and the net profit margin was 12.61%, down 7.65 percentage points, primarily due to stock incentive costs and foreign exchange losses [2] Product and Market Development - The FibroScan device gained significant academic recognition, receiving a "best" rating in U.S. guidelines, with over 5,200 clinical research papers and recommendations from more than 200 liver disease authoritative guidelines and consensus [3] - In 2024, the company's medical device revenue reached 923 million yuan, with rental and other non-sales model revenue accounting for 412 million yuan, representing 44.62% of total revenue, an increase of 5.03 percentage points from the previous year [3] Earnings Forecast and Investment Rating - The company is projected to achieve revenues of 1.692 billion yuan, 2.087 billion yuan, and 2.548 billion yuan for 2025, 2026, and 2027, respectively, with net profits of 218 million yuan, 280 million yuan, and 356 million yuan, corresponding to PE ratios of 37.11X, 28.86X, and 22.76X [4] - The company is expected to continue its focus on liver disease treatment and diagnostics, leveraging the innovative advantages of FibroScan for growth in liver fibrosis diagnosis and treatment [4]

Financial Performance - In 2024, the company achieved operating revenue of 1.349 billion yuan, a year-on-year increase of 16.93% [1] - The net profit attributable to shareholders was 113 million yuan, up 11.54% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 118 million yuan, reflecting a growth of 19.33% [1] - In Q1 2025, the company experienced a slight increase in operating revenue, primarily due to a high base from the previous year, while profits declined due to foreign exchange losses and stock incentive expenses [1] Strategic Initiatives - The company is advancing a "product + service" dual-driven model, enhancing traditional pharmaceutical sales while establishing digital health management services to improve patient adherence and sales of key products [2] - The company is committed to a managed care service model, focusing on liver cancer screening standards and developing comprehensive management solutions from screening to treatment [2] - The company aims to increase liver disease detection and treatment rates while ensuring a win-win situation for insurance, doctors, and patients [2] Research and Development - A national major science and technology project focusing on the prevention and clinical evaluation of primary liver cancer has been launched, involving collaboration with 11 authoritative medical institutions [3] - The project aims to provide comprehensive health solutions for 447 million chronic liver disease patients in China [3] Product Development - The FibroScan liver elastography device has been recognized as the "best" by American guidelines, with over 5,200 clinical research publications supporting its efficacy [4] - By the end of 2024, the company had installed 651 units of FibroScan Go and box globally, with plans to expand its clinical application scenarios in 2025 [4] - The company has established itself as a leader in the fatty liver field, with significant research demonstrating the effectiveness of its products in reducing liver cancer incidence and mortality [4]

Group 1: Financial Performance - In 2024, the company achieved total revenue of CNY 1.349 billion, a year-on-year increase of 16.93% [3] - The net profit attributable to shareholders was CNY 113 million, up 11.54% year-on-year [3] - The cash flow from operating activities was CNY 221 million, a decrease of 27.38% compared to the previous year [3] - For Q1 2025, total revenue was CNY 330 million, a year-on-year increase of 2.35%, while net profit decreased by 32.97% to CNY 28.64 million [3] Group 2: Business Segments - The medical device segment generated revenue of CNY 923 million, a growth of 10.98% year-on-year, with equipment sales contributing CNY 511 million (55.38%) and service fees CNY 412 million (44.62%) [3] - Echosens company reported a net profit of CNY 190.52 million, an increase of 8.26% year-on-year [3] - The company installed 651 units of FibroScan Go and box globally [3] Group 3: Strategic Goals - The vision is to establish a global consensus on liver fibrosis and become a specialized, international management medical group [4] - The mission is to help every family stay away from liver cancer [4] - The core strategy includes five projects: screening, diagnosis, treatment, management, and protection [4] Group 4: Market Opportunities - The Chinese health check market for liver elasticity testing has a potential space of CNY 100 billion [5] - The company aims to cover over 170 health check locations in collaboration with Aikang Guobin [5] - The U.S. market saw a 30% growth in Q1 2025, driven by the approval of the first MASH drug by the FDA [8] Group 5: Product and Service Innovations - The "Hui Gan Bao" insurance product is the first dedicated insurance for chronic liver disease patients, offering various benefits [7] - The company has established a three-tier defense system for liver disease management, focusing on prevention, precise diagnosis, and early treatment [6] - The accuracy of the company's diagnostic equipment exceeds 95%, establishing it as the gold standard for liver fibrosis diagnosis [6]

| 序号 | | 修改前《公司章程》 | 修改后《公司章程》 | | --- | --- | --- | --- | | 1 | 第六条 | 公司注册资本总额为人民币 263,053,100 元。 | 第六条 公司注册资本总额为人民币 264,975,900 元。 | | | 第二十条 | 公司股份总数为 | 第二十条 公司股份总数为 | | 2 | 263,053,100 | 股,均为记名式普通股， | 264,975,900 股,均为记名式普通股， | | | | 全部由股东认购。 | 全部由股东认购。 | 除上述修订条款外，根据《公司法》、《上市公司章程指引》，将全文"股东大会" 调整为"股东会"，《公司章程》其他条款保持不变。详见公司同日刊载于巨潮资讯网 （www.cninfo.com.cn）上的《公司章程》全文。 内蒙古福瑞医疗科技股份有限公司 关于变更公司注册资本、修订《公司章程》并办理工商变更登记的 公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 内蒙古福瑞医疗科技股份有限公司（以下简称"公司"）于 2025 年 4 月 20 日召开第 八 ...

证券代码：300049 证券简称：福瑞股份 公告编号：2025-013 内蒙古福瑞医疗科技股份有限公司 关于向银行申请授信额度的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 内蒙古福瑞医疗科技股份有限公司（以下简称"公司"）于 2025 年 4 月 20 日召开第 八届董事会第十三次会议，审议通过了《关于向银行申请授信额度的议案》。具体情况如 下： 为实现公司的长远发展战略目标，满足研发中心项目建设的资金需求，公司拟向华夏 银行、招商银行、兴业银行等相关金融机构申请不超过 5 亿元的银行授信额度，信贷业务 品种为流动资金贷款、开立银行承兑汇票、国内反向保理、开立国内信用证及国际信用证 等，担保方式为信用担保等，授信期限为一年。 上述授信额度、授信期限等最终以相关金融机构实际审批的授信额度、授信期限为准。 以上授信额度不等于公司的实际融资金额，实际融资金额应在授信额度内，以银行与公司 实际发生的金额为准。公司董事会授权法定代表人或法定代表人指定的授权代理人，在上 述授信额度内签署相关合同、协议等各项法律文件，并由财务部具体办理相关事宜。 公司此次申请授信 ...

2024 年度内部控制评价报告 董事会审计委员会： 根据《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司 规范运作》《企业内部控制基本规范》及其配套指引的规定和要求，审计部对公 司 2024 年度内部控制的有效性进行了审计评价。 一、内部控制评价的依据 根据中华人民共和国财政部等五部委联合发布的《企业内部控制基本规范》 及《企业内部控制评价指引》的要求，结合公司内部控制制度和评价办法，在内 部控制日常监督和专项监督的基础上，对公司截至 2024 年 12 月 31 日内部控制 的设计与运行的有效性进行评价。 二、建立内部控制制度的目标和遵循的原则 （一）内部控制目标 公司建立内部控制制度的目标是合理保证企业经营管理合法合规、资产安全、 财务报告及相关信息真实完整，提高经营效率和效果，促进公司实现发展战略。 1. 合理保证公司各项业务活动合法合规，确保公司管理的各个方面符合国家 有关法律、法规。 2. 建立和完善符合上市公司要求的公司治理结构及内部组织结构，形成科学 的决策机制、执行机制和考核机制，保证公司经营管理目标的全面实现。 3. 建立健全行之有效的风险控制系统，强化风险管理，保证公司业务 ...

内蒙古福瑞医疗科技股份有限公司 2024 年度财务决算报告 内蒙古福瑞医疗科技股份有限公司 2024 年度财务决算报告 公司 2024 年度财务报表及附注业经大信会计师事务所审计，并出具标准无保留 意见的审计报告。现将公司 2024 年度财务决算情况报告如下： 报告期内，公司营业收入同比增长 16.93%。其中器械业务在全球范围内稳步增 长，营业收入同比增长 10.98% ；国内自有药品业务随着市场环境的变化，营销策略 向以学术为主导转变，成效显现，营业收入同比增长 44.31%。 公司股东回报能力进一步提升，实现归属于上市公司股东的净利润 1.13 亿元， 同比增长 11.54%，；加权平均净资产收益率由 6.64%上升至 7.07%。经营活动产生的 现金流量净额为 2.21 亿元，同期减少 0.83 亿元，其中经营活动现金流入同比增加 0.65 亿元，购买商品、接受劳务支付现金同比增加 0.72 亿元，支付给职工及为职工支付 的现金同比增加 0.70 亿元。 2024 年 2023 年 本年比上年增减 2022 年 营业收入（元） 1,349,015,180.45 1,153,733,886.38 16. ...

内蒙古福瑞医疗科技股份有限公司 独立董事提名人声明 提名人王冠一现就提名贺颖奇为内蒙古福瑞医疗科技股份有限公司第八 届董事会独立董事候选人发表公开声明。被提名人已书面同意出任内蒙古福瑞 医疗科技股份有限公司第八届董事会独立董事候选人。本次提名是在充分了解 被提名人职业、学历、专业资格、详细的工作经历、全部兼职等情况后作出的， 本提名人认为被提名人符合相关法律、行政法规、部门规章、规范性文件和深 圳证券交易所业务规则对独立董事候选人任职资格及独立性的要求，具体声明 如下： 一、被提名人不存在《中华人民共和国公司法》第一百四十六条等规定不 得担任公司董事的情形。 是 □ 否 如否，请详细说明：______________________________ 二、被提名人符合中国证监会《上市公司独立董事规则》规定的独立董事 任职资格和条件。 是 □ 否 如否，请详细说明：______________________________ 三、被提名人符合公司章程规定的独立董事任职条件。 是 □ 否 如否，请详细说明：______________________________ 四、被提名人已经参加培训并取得证券交易所认可的相 ...

证券代码：300049 证券简称：福瑞股份 公告编号：2025-011 内蒙古福瑞医疗科技股份有限公司 关于续聘会计师事务所的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 一、拟续聘会计师事务所事项的情况说明 大信会计师事务所（特殊普通合伙）是一家具有证券、期货相关业务资格的会计师 事务所，具备足够的独立性、专业胜任能力、投资者保护能力，在为公司提供审计服务 工作中，遵循独立、客观、公正的执业准则，恪尽职守，较好地完成了公司委托的相关 工作。为保持公司审计工作的连续性，公司拟续聘大信会计师事务所（特殊普通合伙） 为公司 2025 年度审计机构，聘期一年。公司董事会提请股东会授权管理层根据具体审计 要求和审计范围等情况，与审计机构协商确定年度审计费用。 二、拟续聘会计师事务所的基本信息 （一）事务所情况 1、机构信息 大信会计师事务所（特殊普通合伙）（以下简称"大信"）成立于 1985 年，2012 年 3 月转制为特殊普通合伙制事务所，总部位于北京，注册地址为北京市海淀区知春路 1 号 22 层 2206。大信在全国设有 33 家分支机构，在香港设立了 ...